Drug reference

MIFEPRISTONE

MSF Essential Drugs (January 2026)

Source: MSF Essential Drugs (January 2026)
PDF pages: 219

Review source pages for extracted sections and age labels.

Overview

Therapeutic Action

Antiprogestogen

PDF page 219

Indications

Termination of intra-uterine pregnancy up to 22 weeks after the last menstrual period, in combination with misoprostol

PDF page 219

Safety

Contraindications Adverse Effects Precautions

Do not administer to patients with chronic adrenal failure or severe uncontrolled asthma. May cause: gastrointestinal disturbances, vaginal bleeding, uterine contractions, headache. Breast-feeding: no contra-indication for a single dose; to be avoided if multiple doses

PDF page 219

Dose and formulations

Forms And Strengths

200 mg tablet

PDF page 219

Dosage And Duration

200 mg single dose, followed by the administration of misoprostol 1 to 2 days later

PDF page 219

Clinical care

Remarks

Do not use mifepristone in ectopic or molar pregnancy.

PDF page 219

Storage

– – Below 25 °C

PDF page 219

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

MIFEPRISTONE

MSF Essential Drugs (January 2026)

Source: MSF Essential Drugs (January 2026)
PDF pages: 219

Review source pages for extracted sections and age labels.

Overview

Therapeutic Action

Antiprogestogen

PDF page 219

Indications

Termination of intra-uterine pregnancy up to 22 weeks after the last menstrual period, in combination with misoprostol

PDF page 219

Safety

Contraindications Adverse Effects Precautions

PDF page 219

Dose and formulations

Forms And Strengths

200 mg tablet

PDF page 219

Dosage And Duration

200 mg single dose, followed by the administration of misoprostol 1 to 2 days later

PDF page 219

Clinical care

Remarks

Do not use mifepristone in ectopic or molar pregnancy.

PDF page 219

Storage

– – Below 25 °C

PDF page 219

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.